Hepatocellular carcinoma in patients with chronic kidney disease

Table 1 Baseline characteristics of patients with hepatocellular carcinoma, stratified according to the stage of chronic kidney disease n (%)

Variable	Total (n = 440)	Stages 1 and 2 (n = 132)	Stage 3 (n = 263)	Stages 4 and 5 (n = 45)	P value
eGFR1	53.7 ± 27.1	73.5 ± 13.5	50.0 ± 26.4	17.6 ± 8.7	0.000
Age1 (yr)	60.6 ± 11.9	54.4 ± 12.3	63.1 ± 10.5	64.0 ± 11.7	0.000
Male	329 (74.8)	115 (87.1)	182 (69.2)	32 (71.1)	0.000
HBV carrier	271 (61.6)	97 (73.5)	152 (57.8)	22 (48.9)	0.002
HCV carrier	201 (45.7)	42 (31.8)	131 (49.8)	28 (62.2)	0.000
HBV and HCV carrier	62 (14.1)	15 (11.4)	39 (14.8)	8 (17.8)	0.488
Follow-up duration1 (mo)	37.6 ± 37.1	37.0 ± 37.6	40.7 ± 37.6	20.9 ± 27.4	0.013

¹Data are presented as mean ± SD. The P value represents comparison between patients with stages 4 and 5 and patients with stages 1 and 2. eGFR: Estimated glomerular filtration rate; HBV: Hepatitis B virus; HCV: Hepatitis C virus.